SCHEMBL754867

SCHEMBL754867

C[C@@H]1C[C@](C#N)(Nc2cccc(F)c2)CCN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
CYP2D6 P10635 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 2/20 0.38
NPC1 O15118 2/20 0.37
P2RX7 Q99572 1/20 0.37
TSHR P16473 1/20 0.37
MAPK10 P53779 1/20 0.37
KCNH2 Q12809 1/20 0.37
USP2 O75604 3/20 0.36
BRD4 O60885 1/20 0.36
BRD2 P25440 1/20 0.36
BRD3 Q15059 1/20 0.36
CYP2C9 P11712 1/20 0.36
KCNJ6 P48051 1/20 0.36
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36
CYP3A4 P08684 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332171 1.00 ALDH1A1 (0.39) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL4327063 1.00 ALDH1A1 (0.39) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL2553195 1.00 ALDH1A1 (0.39) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL10262476 0.85 JAK2 (0.42) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL1170610 0.85 JAK2 (0.42) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL1170330 0.85 JAK2 (0.42) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL755045 0.85 JAK2 (0.42) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL10293063 0.83 CYP2D6 (0.37) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2
SCHEMBL4464960 0.80 SMN1; SMN2 (0.37) SMN1; SMN2CYP1A2
SCHEMBL4314854 0.80 ALDH1A1 (0.39) ALDH1A1CYP2D6SMN1; SMN2CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211904-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-07-03 US disclosed
EP-1910364-B1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
EP-1910364-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2008-04-16 EP disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed
WO-2007011833-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-01-25 WO disclosed
WO-2007011810-A1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease BACE1, APP, PSEN1 ALDH1A1 717/4885CYP2D6 1697/4885SMN1; SMN2 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.